Penumbra/$PEN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Penumbra
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Ticker
$PEN
Sector
Primary listing
NYSE
Employees
4,500
Headquarters
Website
Penumbra Metrics
BasicAdvanced
$10B
64.32
$4.14
0.69
-
Price and volume
Market cap
$10B
Beta
0.69
52-week high
$310.00
52-week low
$221.26
Average daily volume
408K
Financial strength
Current ratio
6.731
Quick ratio
3.854
Long term debt to equity
14.833
Total debt to equity
15.975
Interest coverage (TTM)
86.04%
Profitability
EBITDA (TTM)
188.651
Gross margin (TTM)
69.31%
Net profit margin (TTM)
12.30%
Operating margin (TTM)
12.95%
Effective tax rate (TTM)
11.73%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
6.70%
Return on equity (TTM)
13.32%
Valuation
Price to earnings (TTM)
64.324
Price to revenue (TTM)
7.728
Price to book
7.67
Price to tangible book (TTM)
8.79
Price to free cash flow (TTM)
67.539
Free cash flow yield (TTM)
1.48%
Free cash flow per share (TTM)
3.941
Growth
Revenue change (TTM)
14.61%
Earnings per share change (TTM)
367.34%
3-year revenue growth (CAGR)
17.13%
10-year revenue growth (CAGR)
23.09%
3-year earnings per share growth (CAGR)
71.71%
10-year earnings per share growth (CAGR)
61.69%
What the Analysts think about Penumbra
Analyst ratings (Buy, Hold, Sell) for Penumbra stock.
Bulls say / Bears say
Penumbra exceeded Q2 2025 revenue and EPS expectations with $339.5 million in sales, up 13.4% year-over-year, which led to a 7% aftermarket increase in its share price (Investing.com)
U.S. thrombectomy revenue jumped 22.6% year-over-year to $188.5 million, and U.S. VTE product sales grew 42%, showing strong domestic demand for Penumbra’s main offerings (Investing.com)
Management raised its 2025 full-year revenue outlook to $1.355–$1.37 billion, above consensus estimates, reflecting confidence in the company’s growth prospects (Nasdaq)
International revenues declined 3.2% in Q2 2025 on a reported basis, reflecting headwinds in China and raising concerns about Penumbra’s ability to sustain growth outside the U.S. (Investing.com)
The U.S. Commerce Department’s Section 232 probe into medical device imports could lead to tariffs on key components, posing supply-chain and margin pressures for Penumbra (Reuters)
Penumbra’s shares trade at a high P/E ratio of 62.57 and a PEG ratio of 2.24, suggesting the stock may be fully valued and limiting near-term upside (American Banking News)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
Penumbra Financial Performance
Revenues and expenses
Penumbra Earnings Performance
Company profitability
Penumbra News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Penumbra stock?
Penumbra (PEN) has a market cap of $10B as of November 09, 2025.
What is the P/E ratio for Penumbra stock?
The price to earnings (P/E) ratio for Penumbra (PEN) stock is 64.32 as of November 09, 2025.
Does Penumbra stock pay dividends?
No, Penumbra (PEN) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next Penumbra dividend payment date?
Penumbra (PEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Penumbra?
Penumbra (PEN) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.